Group 1 - The core point of the article is that Shijiazhuang Pharmaceutical Group announced the sale of a 30.0704% stake in Beijing Guoxin Huijin Co., Ltd. for 230 million yuan, after which the company will no longer hold any shares in the firm [1] - The transaction price was slightly above the assessed value of 226 million yuan, which was based on an independent evaluation with a total equity value of 753 million yuan for Guoxin Huijin as of June 30, 2025 [1] - Guoxin Huijin's main business is in the full media communication sector, specifically mobile financial information services, which is not a core area for Shijiazhuang Pharmaceutical [1] Group 2 - The financial data indicates that Guoxin Huijin is projected to generate revenue of 42.52 million yuan in 2025, with a net loss of 26.94 million yuan, including a loss of 15.72 million yuan in the second half of the year [1] - The purpose of the sale is to optimize resource allocation and focus on the core pharmaceutical business, with proceeds intended to supplement the daily operating funds of Shijiazhuang Pharmaceutical [1] - The company expects to record a loss of approximately 15 million yuan from this transaction, calculated as the difference between the transaction price and the book value of the investment [1]
石药集团：2.3亿元出售国新汇金30.07%股权，预计录得1500万亏损